Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Published:2021-10-26 Issue:1 Volume:11 Page:7-19
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Kandadi Muralidharan Kumar¹,Tong Xiao¹,Kowalski Kenneth G.²,Rajagovindan Raj³,Lin Lin¹,Budd Haberlain Samantha⁴,Nestorov Ivan¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics Biogen Cambridge Massachusetts USA

2. Kowalski PMetrics Consulting, LLC Northville Michigan USA

3. Development Imaging Biogen Cambridge Massachusetts USA

4. Clinical Development Biogen Cambridge Massachusetts USA

Funder

Biogen

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12728

Reference15 articles.

1. Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

2. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

3. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

4. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

5. EMERGE and ENGAGE topline results: Phase 3 studies of aducanumab in early Alzheimer's disease;Budd Haeberlein S;Alzheimer's Dement,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease;Med;2024-09

2. Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer’s Disease Therapy;2024-05-01

3. Monoclonal Antibody Therapy in Alzheimer’s Disease;Pharmaceutics;2023-12-29

4. Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs;Journal of Neurosciences in Rural Practice;2023-10-07

5. Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials;Journal of Pharmacokinetics and Pharmacodynamics;2023-01-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3